CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the COVID-19 pandemic ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

Live Updates Live Coverage Updates appear automatically as they are published. Investors Don't Like the Taste of Yum! 9:37 am ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

Pfizer reported a jump in second-quarter profits Tuesday behind higher sales of Covid-19 products and some other pharmaceuticals, while also benefiting from lower expenses.